If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the ...

Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for real-time, ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

DexCom, Inc. (NASDAQ:DXCM) is among the Best Healthcare Stocks. On June 23, DexCom, Inc. (NASDAQ:DXCM) announced that the FDA ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...